XENO (Xeno Transplants) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 26, 2026)


What is Xeno Transplants Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Xeno Transplants's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

XENO vs PRTX, GWSN, HSTC: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Xeno Transplants's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Xeno Transplants Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xeno Transplants's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Xeno Transplants's Margin of Safety % (DCF Earnings Based) falls into.


Xeno Transplants Business Description

Address 143 Gardner Road, Brookline, MA, USA, 02445
Xeno Transplants Corp is a bio-technology research and development company, which intends to develop therapeutic applications of organs and cells derived from genetically engineered pigs as a transplant alternative to limited human donor sources.